Amyloid-targeting therapy study for Alzheimer's disease and healthy participants
Part of Brain & nervous system, Mental health clinical trials.
This study tests new treatments that target amyloid plaques in the brain, which are linked to Alzheimer's disease. It includes both healthy people and those with mild cognitive impairment or mild-to-moderate Alzheimer's, to see if the treatments are safe and how they affect the body.
Summary written for real people, not researchers, by Clin2.
Who can take part
- If you have Alzheimer's disease or mild cognitive impairment, you must be between 55 and 85 years old. If you are healthy, you must be between 18 and 45.
- You must not have serious or unstable medical conditions like heart, lung, liver, kidney, or neurological diseases.
- You must not have allergies to the study drugs (monoclonal antibodies, diphenhydramine, epinephrine, or methylprednisolone).
- You must not have had cancer in the last 5 years, except for certain skin cancers that were removed.
- You must not have taken any amyloid-targeting therapy or participated in a study with an investigational drug in the last 30 days.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new drug called LY4405094 in healthy people and people with Alzheimer's disease. It aims to see if the drug is safe and how it works, but people with certain allergies (especially to adhesives) cannot join.
This trial tests a new medicine called LY4006895 in two groups: healthy volunteers and people with early symptomatic Alzheimer's disease. It aims to see how the drug works in the body and if it might help memory and thinking.
This study tests an experimental drug called LY3439539 in people with early-stage Alzheimer's disease. The drug is designed to target protein changes in the brain that may slow memory loss and cognitive decline.
This Phase 3 study looks for blood/brain “biomarkers” linked to aging, memory changes, and early brain degeneration. It may help researchers better identify who is at risk and how biology relates to thinking and memory, using brain scans and thinking tests.
This study tests an experimental drug (LY3954068) for people with early Alzheimer's disease. It aims to see if the drug is safe and may slow memory loss. You'll need a PET scan to measure tau protein in the brain and have a study partner who can help attend appointments.
This study tests antibody treatments that target amyloid plaques in the brain for people with mild memory or thinking problems. It may help determine if you are a candidate for these new drugs and monitors your safety through regular scans and checkups.
Hear when a new Amyloid trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.